Supplemental Material 0602 in T1D manuscript 06042020_cx01.xlsx (310.13 kB)

Failed Genetic Protection: Type 1 Diabetes in the presence of HLA-DQB1*06:02

Download (310.13 kB)
posted on 12.06.2020 by Ada Admin, Kimber M. Simmons, Angela M. Mitchell, Aimon A. Alkanani, Kristen A. McDaniel, Erin E. Baschal, Taylor Armstrong, Laura Pyle, Liping Yu, Aaron W. Michels
Certain human leucocyte antigen (HLA) class II genes increase the risk for type 1 diabetes (T1D) development while others provide protection from disease development. HLA class II alleles encode major histocompatibility complex proteins on antigen presenting cells, which function to present peptides and activate CD4 T-cells. The DRB1*15:01 (DR15)-DQA1*01:02-DQB1*06:02 (DQ6) haplotype provides dominant protection across all stages of T1D and is a common haplotype found in Caucasians but present in <1% of people with T1D. Knowing which metabolic, immunologic and genetic features are unique to individuals who fail genetic protection and develop T1D is important for defining the underlying mechanisms of DQB1*06:02-mediated protection. We describe a T1D cohort with DQB1*06:02 (n=50) and compare them to individuals with T1D and without DQB1*06:02 (n=2,759) that were identified over the last 26 years at the Barbara Davis Center for Diabetes. The age at diagnosis was similar between the cohorts and normally distributed throughout childhood and early adulthood. The average hemoglobin A1c was 10.8 ± 2.8% (95 ± 7mmol/mol) at diagnosis in those DQB1*06:02+. The majority of T1D DQB1*06:02+ individuals were positive for one or more islet autoantibodies; however, there was a greater proportion that were islet autoantibody negative compared to those T1D DQB1*06:02- individuals. Interestingly, DQB1*03:02, which confers significant T1D risk, was only present in those DQB1*06:02+ individuals with islet autoantibodies. This is one of the largest studies examining patients presenting with clinical T1D in the presence of DQB1*06:02, which provides a population to study the mechanisms of failed genetic protection against T1D.


This work was supported by NIH Grants (DK095995, DK108868, DK110845, DK032083, DK094712); the Juvenile Diabetes Research Foundation; the Children’s Diabetes Foundation (2-SRA-2016-202-5-B); and the Colorado Clinical and Translational Science Institute (TR001082).



Logo branding